$0.37
+0.00 (+0.54%)
Open$0.36
Previous Close$0.37
Day High$0.37
Day Low$0.35
52W High$3.87
52W Low$0.32
Volume—
Avg Volume4.51M
Market Cap80.67M
P/E Ratio—
EPS$-0.75
SectorBiotechnology
Analyst Ratings
Buy
16 analysts
Price Target
+7,312.1% upside
Current
$0.37
$0.37
Target
$27.41
$27.41
$18.46
$27.41 avg
$44.08
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 46.27M | 95.94M | 101.30M |
| Net Income | -162,617,197 | 13.15M | 13.02M |
| Profit Margin | -351.5% | 13.7% | 12.9% |
| EBITDA | -154,088,246 | 20.01M | 19.52M |
| Free Cash Flow | — | 11.25M | 11.45M |
| Rev Growth | — | +8.6% | -0.1% |
| Debt/Equity | 6.70 | 1.02 | 0.99 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |